Anti-islet cell and anti-insulin antibody production was studied over a 12-mo period in 82 recently diagnosed diabetics randomly receiving either cyclosporin or placebo. Cyclosporin had only minimal effects on the production of anti-islet cell antibodies whether directed to islet cytoplasmic (immunofluorescence) or membrane (cytotoxicity assay) antigens even in patients undergoing remission. These data suggest that these antibodies do not play a major role in the pathogenesis of the disease particularly since their (irregular) presence is not predictive of the clinical response to cyclosporin. Conversely, cyclosporin completely suppressed the synthesis of antibodies elicited by exogenous insulin irrespective of the insulin doses received, and decreased the autoantibody production against thyroid antigens, indicating that cyclosporin has variable effects on antibody production against various antigens.
Introduction
Cyclosporin A has recently been shown to increase the length and rate of remissions in insulin-dependent diabetes mellitus (IDDM)' (1) (2) (3) . This major therapeutic breakthrough, which confirms in man similar data previously reported in rodent models (BB rat, NOD mouse) (4-7), brings strong support for an autoimmune origin ofIDDM. Such an autoimmune nature has already been strongly suggested by several lines of evidence. Anti-islet cell antibodies are commonly observed at an early stage of the disease (8, 9) . In Caucasian populations, IDDM has been shown to associate with HLA-DR3 and/or DR4 antigens (10) . Evidence that cell-mediated immunity has a major involvement in the lesion of the insulin-producing 13 -cell has been obtained from the high proportion of T lymphocytes observed in the cellular infiltrate within the islets of Langerhans in recent onset IDDM (1 -13) , from the capacity of purified T lymphocytes to inhibit insulin release by islet 1 . Abbreviations used in this paper: AIA, anti-insulin antibodies; CF-ICA, complement-fixing islet cell antibodies; HbAlc, hemoglobin Alc; ICA, islet cell antibodies; IDDM, insulin-dependent diabetes mellitus; S-ICA, sensitized ICA. cells in vitro (14, 1 5) , and from the potential role ofinterleukin 1 in islet 3-cell destruction (16, 17) . Transfer experiments clearly point to a predominant role of T lymphocytes in the NOD mouse model for spontaneous IDDM (18) .
The problem remains however of the existence of a significant percentage of cyclosporin-resistant patients, and more generally of the mode of action of cyclosporin in this indication. We report here studies aimed at determining the immunological effects of cyclosporin A in IDDM patients that contribute to resolve these questions. Importantly, since data obtained in this investigation were compared with control data collected in a placebo group randomized with the cyclosporin A group, conclusions can be drawn despite the difficult problem of interference with the spontaneous evolution of immunological parameters in IDDM.
Methods
Patients. 82 patients in whom diagnosis of IDDM was established according to the World Health Organization criteria (19) were included in this study. These patients represent a large and unselected sample of the previously reported French randomized double-blind trial (3). 42 patients received 7.5 mg/kg body wt per d in a single oral dose of cyclosporin in olive oil (100 mg/ml) for 6-12 mo. 40 patients received placebo in the form ofan equal volume (0.075 ml/kg body wt) of olive oil for 6-12 mo. The dosage of either cyclosporin A or placebo was increased to 10 mg/kg and 0.01 ml/kg body wt per d, respectively, at 3 mo, in case of persistent insulin requirement, to obtain the metabolic control defined below. The treatment was interrupted after 6 mo in case of failure. Failure was defined as insulin requirement above 0.25 U/kg body wt per d. Remission referred to decreased insulin requirement. Incomplete remission was defined as insulin requirement below 0.25 U/kg body wt per d to obtain a metabolic control defined by fasting glycemia below 7.8 mmol/liter, postprandial glycemia below 1.1 mmol/liter, and glycosylated hemoglobin Alc (HbAlc) below 7.5%. Normal value for HbAl was 5.0±0.8% (2 SD). Complete remission was defined by fasting and postprandial glycemia, respectively, below 7.8 and 1.1 nmol/liter, and HbAlc below 7.5% in the absence of exogenous insulin or oral hypoglycemic agents.
Islet cell antibody (ICA) determination (immunofluorescence). ICA were determined by indirect immunofluorescence on frozen sections ofa human group 0 pancreas using a fluoresceinated anti-human IgG serum (Wellcome Diagnostics, Dartford, England) as described by Bottazzo et al. (8) . Complement-fixing ICA (CF-ICA) were determined on similar sections using a fluoresceinated anti-C3 serum (Dakopatts a/s, Glostrup, Denmark) (20) . A technique using pretreatment of sera by aprotinin was performed as described by Elliott et al. (21) to determine sensitized ICA (S-ICA). Antibody titers were determined by serial log2 dilutions. The precision and accuracy of ICA determination using the same pancreas as that used in this study was previously evaluated by the standard curve under the code number 4 as part of the First International Workshop on the standardization of cytoplasmic ICA (22). Intraassay variation was 95.6% when determining S-ICA titers of 22 samples studied blind twice. The specificity and sensitivity of ICA determination were 98.75 and 69%, respectively, using the same pancreas as that used in the present study.
Cytotoxic antibodies. Cytotoxic antibodies to beta cells were determined as previously described by Dobersen et al. (23) . Rat islet cell suspensions were obtained from 8-wk-old Wistar rats using collagenase and dispase as previously described. Islet cells were washed and incubated at 370C with 100 ACi of ['tCr]sodium chromate per 5 X 10 islet cells for I h. 5"Cr-labeled cells were distributed into 96-well plates at a density of 5 X I09 cells per well. Cells were incubated for 1 h with a 1:3 dilution of control and test sera at 20'C, then for another hour with a 1:15 dilution of rabbit serum preadsorbed with rat spleen cells. Each serum was tested in triplicate. 100-,ul aliquots were finally removed from each well and counted in a Packard gammacounter. Maximal chromium release was obtained by incubating 5 X 103 5"Cr-labeled cells with I ml distilled water for 2 h. The specificity and sentitivity of cytotoxic antibody determination were 90 and 46%, respectively, in the experimental conditions of the test.
HLA typing. All patients were typed for class II (DRl-DRwl0) major histocompatibility complex antigens as previously described (24) .
Anti-insulin antibodies (AIA). AIA were determined by immunoprecipitation of '25I-labeled insulin (Novo, Copenhagen, Denmark) as previously described (25, 26) with slight modifications consisting of a preincubation of tested sera with charcoal. The sensitivity and specificity of the assay were 57 and 100%, respectively, in the experimental conditions used in this study.
Anti-thyroid antibodies. Anti-thyroglobulin and anti-microsomal antibodies were evaluated by a passive hemagglutination test using a commercial kit (Wellcome Diagnostics).
Cyclosporinemia. Cyclosporinemia was evaluated in total blood as a trough level 24 h after oral intake ofthe drug using a kit (Sandoz Ltd., Basel, Switzerland).
Expression ofdata. CF-ICA, ICA, S-ICA, anti-thyroglobulin and anti-microsomal antibody titers were expressed as the log2 value ofthe last positive dilution oftested sera. AIA were expressed as a percentage of ligand-bound radioactivity. Percentages above 1.9% (mean + 2 SD) were considered positive. Cytotoxic antibodies to beta cells were expressed using the following index: tested serum (cycles per minute)/ maximal release (cycles per minute) X 100. Indexes > 33% (mean of control sera + 2 SD) were considered positive. The statistical comparison ofantibody titers observed in various groups was performed using the Student's t test. (Fig. 2) . There was no significant difference in the evolution of cytotoxic antibodies depending on cyclosporinemia levels (data not shown).
Results
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AIA. AIA were detected in 22 (55%) placebo-treated patients and 21 (50%) cyclosporin A-treated patients at inclusion in the trial (which occurred 3-5 wk after initiation of insulin therapy). Follow up showed significantly lower levels ofAIA in the cyclosporin A-treated group as compared with the placebo group at both 3 and 6 mo (Fig. 3) . Cyclosporin A prevented the production of AIA in patients without detectable antibodies at the initiation of immunosuppressive therapy: the percentage of patients without detectable AIA after 6 mo of cyclosporin treatment (50%) was identical to that observed at entry in the trial. In the placebo group, the percentage of patients with detectable AIA rose from 55% at entry to 87.5% at 6 mo.
Additionally, cyclosporin A strongly reduced preexisting AIA production when it was detectable at initiation of therapy. The level of AIA after 6 mo of cyclosporin treatment was lower than that at initiation of therapy in all patients but one. This later patient initially showed an increase in AIA levels from 2.2% of bound 125-iodine insulin to 15.1% at 3 mo of cyclosporin A therapy, then a decrease to 9.2% at 6 mo. Comparatively, in the placebo group, the percentage ofbound '25-iodine insulin at 6 mo was significantly higher than that at entry into the trial in all patients but one, whose level was 1.8% at 6 mo, compared with 1.9% at initiation of therapy.
When considering only patients who did not stop insulin injections and were classified as failure at 6 months, the level of AIA was significantly lower at 3 and 6 mo in the cyclosporin A-treated group as compared with the placebo group (Fig. 4) . A rebound effect on the production of AIA was observed when treatment with cyclosporin A was stopped at 6 mo. The level of AIA was higher at 9 and 12 mo in patients who stopped cyclosporin A treatment (failure) as compared with patients who stopped placebo at 6 mo, although this difference did not reach statistical significance (Fig. 4) . It is important to stress that the mean daily insulin dose was not significantly different in both groups from the 7th to the 12th mo (33±3 SE and 31±3 SE U/d, respectively). Finally, the occurrence of a relapse in patients in complete remission was never preceded by an increase in AIA (Table  III) . This precludes any predictive value of AIA in patients in complete remission.
Anti-thyroid antibodies. Eight patients in the cyclosporin A group had circulating anti-microsomal antibodies, compared to three in the placebo group. One of the eight patients in the cyclosporin A group also had anti-thyroglobulin antibodies while another patient had isolated anti-thyroglobulin antibodies. All three patients in the placebo group with antimicrosomal antibodies also had anti-thyroglobulin antibodies. The 
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cyclosporin A-treated (14) patients over a 12-mo 4019 (14) follow-up period. cantly after 6 mo of treatment in the cyclosporin A group as opposed to the placebo group (Fig. 5) . Although the number of patients with anti-thyroglobulin antibodies is small in both groups, it is worth noting that anti-thyroglobulin antibodies disappeared in one patient, decreased by five log2 dilutions in the other patient under cyclosporin A, and remained unmodified or increased by one and two dilutions in the three patients receiving placebo when comparing the 6-mo value to that detected at entry into the trial. Out of the eight patients with detectable anti-microsomal antibodies, six also had cytoplasmic ICA. In these six positive patients, the titer of S-ICA remained unmodified at six months, while anti-microsomal antibodies became undetectable in one, decreased by two dilutions in three, by four dilutions in one, and remained unmodified in one patient. HLA-DR phenotype. 88% of treated patients were either HLA-DR3 or DR4. 30% of patients were both DR3 and DR4. No significant difference was detected in the titer of ICA, cytotoxic antibodies to islet cells, or AIA in patients of the various DR phenotypes, with the exception of non-DR3, non-DR4 patients, who showed a lower (statistically nonsignificant) incidence of cytoplasmic and cytotoxic anti-islet antibody (Table IV) . In addition, since the incidence of remissions was not different in DR3-X, DR4-X, DR3-4, and non-DR3, non-DR4 patients, this preliminary analysis provided no clear evidence that the HLA-DR phenotype allowed any prediction in terms of remission or relapse in clinical remitters.
Discussion
ICA were detected in 42% of all patients before starting cyclosporin A and placebo treatment using the conventional method described by Bottazzo et al. (8, 20) . With the complement fixation method positivity was even lower ( 17%). These figures are below the percentages reported in other series. We
have not found such a discrepancy, however, in other groups (30) . The absence of correlation between ICA titers and the induction of remission, and the delayed reduction in ICA titer as compared with the onset of remission, suggest that ICA are secondary to rather than responsible for the islet ,8-cell destruction. In fact, the absence of an obvious effect of cyclosporin A on anti-islet antibody production contrasted with the clear-cut effect observed in the same patients with 6 mo of cyclosporin therapy (concomitantly with complete remissions) on T cell capacity to inhibit insulin release in vitro (2) .
The minor and late reduction of ICA titers in the cyclosporin A group after a 12-mo treatment follow-up may indi- 12 Mondis is as in Fig. 1 , , , (41) . In spontaneous or induced autoimmune diseases in animals, cyclosporin A treatment inhibits autoantibody production when given before rather than after the appearance of autoantibodies, as shown in thyroiditis (42, 43) and experimental myasthenia gravis (44) . Conversely, cyclosporin shows little or no effect on autoantibody production in experimental uveitis in the rat (45) and in spontaneous thyroiditis in the obese strain chicken (46) . The only exception is in lupus mice, where an established anti-DNA autoantibody production has been shown to be inhibited by cyclosporin A (47). To date, very little is known on the effect of cyclosporin A on autoantibody production in human autoimmune diseases. Disappearance of anti-skin antibodies has been reported in patients suffering from bullous pemphigoid (48) . By contrast, no inhibition of anti-double-stranded and antinuclear DNA antibodies has been reported in systemic lupus erythematosus over a 6-mo follow-up period (49) . Finally, it is interesting to note that in the responses to exogenous keyhole limpet hemocyanin and tetanus toxoid, cyclosporin A-treated patients with chronic uveitis showed a significant inhibition of delayed-type cutaneous hypersensitivity reactions but no significant reduction of antibody production (50) . Conversely, a moderate inhibition of the humoral response to influenza vaccination has been reported in cyclosporin A-treated renal transplant patients (5 1).
Our data indicate a clearcut difference in the action of cyclosporin A on established anti-islet autoantibody production and the immune response to exogenous insulin. Since the mean duration of insulin therapy was 22 d before starting cyclosporin A treatment, we assume that AIA were not autoantibodies as may be found in diabetic patients before initiation of insulin therapy, but were antibodies directed at exogenous insulin. Importantly, the decreased level of AIA in patients treated with cyclosporin A was observed independently of the induction of remission. That established AIA production was strongly inhibited by cyclosporin A treatment is discordant with the differential action of cyclosporin A on antibody production discussed above, depending on its introduction before or after the antigenic challenge. When considering anti-thyroid autoantibody titers, it appears that cyclosporin A also inhibited established anti-thyroid antibody production at variance with the absence of obvious effect observed on antiislet antibody production. This difference may be interpreted as indicating either a different level of autoimmunization against the two organs or a higher involvement of T cells in thyroiditis as compared with IDDM. The latter hypothesis is unlikely, since anti-islet cell autoantibodies are of the IgG (presumably thymus dependent) isotype.
